Keyphrases
Invasive Urothelial Carcinoma
100%
Intravesical Immunotherapy
100%
Canine
100%
Chitosan
81%
Interleukin-12 (IL-12)
66%
Intravesical
36%
Bladder Cancer
27%
Bladder
18%
Recommended Dose
18%
Mucoadhesive
9%
T-cell Mediated
9%
Bladder Tumor
9%
Tumor Immune Microenvironment
9%
Faithful Representation
9%
Tumor mutational Burden
9%
Immunotherapy Response
9%
Neoantigen
9%
Clinical Laboratory Test
9%
Surgical Removal
9%
Novel Immunotherapy
9%
Systemic Uptake
9%
Invasive Bladder Cancer
9%
Clinical Examination Test
9%
T-cell Clonality
9%
Metastasis Sites
9%
Canine Bladder Cancer
9%
Molecular Subtypes
9%
Tumorigenesis Mechanism
9%
Urinary Bladder
9%
Dose-escalation Study
9%
Anti-tumor Response
9%
Chitosan Biopolymer
9%
Pet Dogs
9%
Antitumor
9%
Checkpoint Inhibitors
9%
Checkpoint Immunotherapy
9%
T Cell Infiltration
9%
Abscopal Response
9%
Lethal Infection
9%
Immune Response
6%
Specific Intent
6%
Cancer Patients
6%
Metastasis
6%
Human Trials
6%
Immunophenotyping
6%
Immunological Response
6%
Rodent Models
6%
Recombinant
6%
Tumor Immunity
6%
Patient Benefit
6%
Clinical Translation
6%
Medicine and Dentistry
Transitional Cell Carcinoma
100%
Chitosan
100%
Immunotherapy
66%
Interleukin 12
50%
Bladder
40%
Recommended Drug Dose
20%
Bladder Cancer
20%
T Cell
20%
Metastatic Carcinoma
13%
Malignant Neoplasm
13%
Bladder Tumor
10%
Clonal Variation
10%
Laboratory Test
10%
Cellular Infiltration
10%
Tumor Immune Microenvironment
10%
Invasive Bladder Cancer
10%
Carcinogenesis
6%
Biopolymer
6%
Clinical Examination
6%
Immune Response
6%
Clinical Trial
6%
Disease
6%
Immunophenotyping
6%
In Vitro
6%
Neoplasm
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chitosan
100%
Transitional Cell Carcinoma
100%
Immunotherapy
66%
Interleukin 12
50%
Bladder Cancer
30%
Malignant Neoplasm
13%
Neoplasm
13%
Mouse
13%
Bladder Tumor
10%
Pet Animal
10%
Preclinical Study
6%
Carcinogenesis
6%
Clinical Trial
6%
Disease
6%
Biopolymer
6%
Elimination
6%